Abstract
We report a case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a complete response to trastuzumab and paclitaxel treatment. A 37-year-old woman was referred to our hospital for right breast swelling with broad skin redness and right axillary tumor. Ipsilateral infraclavicular and contralateral axillary lymph nodes swelling were also recognized. The histopathological findings of core-needle biopsy specimens from primary breast tumor and ipsilateral axillary lymph node were invasive ductal carcinoma with a micropapillary component. Immunohistochemical examination gave a negative result for estrogen receptor (ER)/progesterone receptor (PgR), and overexpression of HER-2 (Hercep Test 3+). Advanced inflammatory breast cancer with an invasive micropapillary component was diagnosed (T4d N3 M1 (LYM), stage IV). The patient was treated with combination chemotherapy using weekly paclitaxel and trastuzumab. After administration of three courses, the breast swelling, skin redness, and lymph node swelling disappeared completely. She maintained complete remission of disease for 12 months and was judged to have a clinically complete response by the RECIST criteria. Invasive micropapillary carcinoma is known to be an aggressive histological type associated with a high incidence of lymph node metastasis and poor prognosis. This is the first reported case of advanced inflammatory breast cancer with an invasive micropapillary component showing a clinically complete response to trastuzumab-containing treatment. This report suggests trastuzumab-containing chemotherapy is a promising therapy for HER-2-positive advanced invasive micropapillary carcinoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Luna-More S, Gonzalez B, Acedo C et al (1994) Invasive micropapillary carcinoma of the breast. A new special type of invasive mammary carcinoma. Pathol Res Pract 190(7):668–674
Guo X, Chen L, Lang R et al (2006) Invasive micropapillary carcinoma of the breast: association of pathologic features with lymph node metastasis. Am J Clin Pathol 126(5):740–746
Chen L, Fan Y, Lang RG et al (2008) Breast carcinoma with micropapillary features: clinicopathologic study and long-term follow-up of 100 cases. Int J Surg Pathol 16(2):155–163
Pettinato G, Manivel CJ, Panico L et al (2004) Invasive micropapillary carcinoma of the breast: clinicopathologic study of 62 cases of a poorly recognized variant with highly aggressive behavior. Am J Clin Pathol 121(6):857–866
Paterakos M, Watkin WG, Edgerton SM et al (1999) Invasive micropapillary carcinoma of the breast: a prognostic study. Hum Pathol 30(12):1459–1463
Varga Z, Zhao J, Ohlschlegel C et al (2004) Preferential HER-2/neu overexpression and/or amplification in aggressive histological subtypes of invasive breast cancer. Histopathology 44(4):332–338
Zekioglu O, Erhan Y, Ciris M et al (2004) Invasive micropapillary carcinoma of the breast: high incidence of lymph node metastasis with extranodal extension and its immunohistochemical profile compared with invasive ductal carcinoma. Histopathology 44(1):18–23
Kim MJ, Gong G, Joo HJ et al (2005) Immunohistochemical and clinicopathologic characteristics of invasive ductal carcinoma of breast with micropapillary carcinoma component. Arch Pathol Lab Med 129(10):1277–1282
De la Cruz C, Moriya T, Endoh M et al (2004) Invasive micropapillary carcinoma of the breast: clinicopathological and immunohistochemical study. Pathol Int 54(2):90–96
Alvarado-Cabrero I, Alderete-Vazquez G, Quintal-Ramirez M et al (2009) Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings. Ann Diagn Pathol 13(3):151–157
Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672
Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684
Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792
Vogel CL, Tan-Chiu E (2005) Trastuzumab plus chemotherapy: convincing survival benefit or not? J Clin Oncol 23(19):4247–4250
Macia Escalante S, Rodriguez Lescure A, Pons Sanz V et al (2006) A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapy. Clin Transl Oncol 8(10):761–763
Rai Y, Sagara Y, Takahama T et al (2007) Preoperative therapy with trastuzumab and paclitaxel in a stage IV advanced breast cancer with complete pathologic response. Gan To Kagaku Ryoho 34(1):65–68
Hortobagyi GN (1998) Treatment of breast cancer. N Engl J Med 339(14):974–984
Bruzzi P, Del Mastro L, Sormani MP et al (2005) Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol 23(22):5117–5125
Conflict of interest statement
No author has any conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Shigematsu, H., Nakamura, Y., Tanaka, K. et al. A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment. Int J Clin Oncol 15, 615–620 (2010). https://doi.org/10.1007/s10147-010-0093-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-010-0093-2